[go: up one dir, main page]

TR199900730T2 - S�v� alendronat form�lasyonlar� - Google Patents

S�v� alendronat form�lasyonlar�

Info

Publication number
TR199900730T2
TR199900730T2 TR1999/00730T TR9900730T TR199900730T2 TR 199900730 T2 TR199900730 T2 TR 199900730T2 TR 1999/00730 T TR1999/00730 T TR 1999/00730T TR 9900730 T TR9900730 T TR 9900730T TR 199900730 T2 TR199900730 T2 TR 199900730T2
Authority
TR
Turkey
Prior art keywords
lasyonlar
alendronate
formulation
hcl
pharmaceutically acceptable
Prior art date
Application number
TR1999/00730T
Other languages
English (en)
Turkish (tr)
Inventor
J. Nerurkar Maneesh
H. Hunke William
Ostovic Drazen
Original Assignee
Merck & Co., Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700541.7A external-priority patent/GB9700541D0/en
Application filed by Merck & Co., Inc filed Critical Merck & Co., Inc
Publication of TR199900730T2 publication Critical patent/TR199900730T2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR1999/00730T 1996-10-04 1997-10-02 S�v� alendronat form�lasyonlar� TR199900730T2 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2676596P 1996-10-04 1996-10-04
GBGB9700541.7A GB9700541D0 (en) 1997-01-13 1997-01-13 Liquid alendronate formulation
US3600297P 1997-01-22 1997-01-22

Publications (1)

Publication Number Publication Date
TR199900730T2 true TR199900730T2 (xx) 1999-07-21

Family

ID=27268667

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00730T TR199900730T2 (xx) 1996-10-04 1997-10-02 S�v� alendronat form�lasyonlar�

Country Status (20)

Country Link
EP (1) EP1007054A4 (xx)
JP (1) JP2001501222A (xx)
CN (1) CN1238691A (xx)
AU (1) AU723357B2 (xx)
BG (1) BG103306A (xx)
BR (1) BR9712197A (xx)
CA (1) CA2267370A1 (xx)
CZ (1) CZ116999A3 (xx)
EA (1) EA001213B1 (xx)
EE (1) EE03669B1 (xx)
HU (1) HUP0000125A3 (xx)
IL (1) IL129127A0 (xx)
IS (1) IS5012A (xx)
NO (1) NO991569L (xx)
NZ (1) NZ334836A (xx)
PL (1) PL332496A1 (xx)
SK (1) SK42999A3 (xx)
TR (1) TR199900730T2 (xx)
WO (1) WO1998014196A1 (xx)
YU (1) YU17499A (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058708A1 (en) 2001-01-23 2002-08-01 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2007031785A2 (en) * 2005-09-16 2007-03-22 Selamine Ltd Bisphosphonate formulation
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
JP2010043119A (ja) * 2009-10-16 2010-02-25 Gador Sa 骨の代謝病の予防および/または治療のための組成物、その組成物の調製方法およびその使用
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy

Also Published As

Publication number Publication date
CN1238691A (zh) 1999-12-15
CA2267370A1 (en) 1998-04-09
BR9712197A (pt) 1999-08-31
WO1998014196A1 (en) 1998-04-09
NZ334836A (en) 2000-11-24
EA199900352A1 (ru) 1999-08-26
HUP0000125A3 (en) 2001-04-28
NO991569D0 (no) 1999-03-30
AU4644897A (en) 1998-04-24
SK42999A3 (en) 2000-01-18
BG103306A (en) 2000-01-31
AU723357B2 (en) 2000-08-24
EE9900113A (et) 1999-10-15
CZ116999A3 (cs) 1999-09-15
NO991569L (no) 1999-06-04
EP1007054A1 (en) 2000-06-14
EE03669B1 (et) 2002-04-15
IL129127A0 (en) 2000-02-17
EP1007054A4 (en) 2000-07-19
HUP0000125A2 (hu) 2000-06-28
YU17499A (en) 1999-11-22
EA001213B1 (ru) 2000-12-25
JP2001501222A (ja) 2001-01-30
PL332496A1 (en) 1999-09-13
IS5012A (is) 1999-03-26

Similar Documents

Publication Publication Date Title
TR200101499T1 (tr) Azepinoindol türevleri, hazırlanmaları ve kullanımları.
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
DK1200418T3 (da) Nematodicide trifluorbutener
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ATE435648T1 (de) Derivaten von nodulisporen säure
CO5611160A2 (es) Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
FR12C0004I2 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
BR9902086A (pt) Formulações farmacêuticas.
EP0975602A4 (en) IMIDAZOLE AND IMIDAZOLE DERIVATIVES AND THEIR USE
ATE425253T1 (de) Tribonektine
DE50004334D1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
TR199900730T2 (xx) S�v� alendronat form�lasyonlar�
HRP20010878B1 (en) Ziprasidone suspension
BR9909357A (pt) Solução ou suspensão de mirtazapina em mistura com água, formulação farmacêutica compreendendo mirtazapina, e, uso de mirtazapina
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
SE0004710L (sv) System och förfarande
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
UY27373A1 (es) Formulaciones de interferón beta-humano
DE69936052D1 (de) N1 modifizierte glycopeptide
DE59812581D1 (de) Cyclopeptidderivate mit integrin-inhibitor-eigenschaften
MXPA03008837A (es) Una composicion farmaceutica estable de pravastatina.
DK0977871T3 (da) Neurotrypsin
YU87501A (sh) Farmaceutski kompleksi